CLSA Initiates Coverage on Editas Medicine (EDIT)

Stock analysts at CLSA began coverage on shares of Editas Medicine (NASDAQ:EDIT) in a research note issued on Tuesday, The Fly reports. The brokerage set an “underperform” rating on the stock.

Several other research firms have also issued reports on EDIT. ValuEngine lowered shares of Editas Medicine from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. SunTrust Banks raised shares of Editas Medicine from a “hold” rating to a “buy” rating and increased their price target for the stock from $17.00 to $45.00 in a research report on Tuesday, January 23rd. Finally, Cowen reissued a “buy” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Editas Medicine presently has a consensus rating of “Hold” and a consensus target price of $30.73.

Editas Medicine (NASDAQ:EDIT) opened at $32.85 on Tuesday. Editas Medicine has a 52-week low of $13.12 and a 52-week high of $41.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 10.12 and a quick ratio of 10.12. The stock has a market cap of $1,528.27, a PE ratio of -10.14 and a beta of 4.79.

In other news, CEO Katrine Bosley sold 8,333 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $36.18, for a total transaction of $301,487.94. Following the completion of the sale, the chief executive officer now owns 1,338,898 shares of the company’s stock, valued at $48,441,329.64. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Andrew A. F. Hack sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $24.81, for a total transaction of $124,050.00. Following the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at approximately $124,050. The disclosure for this sale can be found here. Insiders sold 84,648 shares of company stock valued at $2,687,509 in the last three months. Company insiders own 19.40% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can increased its holdings in shares of Editas Medicine by 519.9% during the third quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after buying an additional 4,159 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Editas Medicine by 4.1% during the second quarter. Royal Bank of Canada now owns 9,364 shares of the company’s stock worth $157,000 after buying an additional 372 shares in the last quarter. Martingale Asset Management L P acquired a new stake in shares of Editas Medicine during the fourth quarter worth approximately $219,000. Plancorp LLC acquired a new stake in shares of Editas Medicine during the fourth quarter worth approximately $235,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Editas Medicine during the fourth quarter worth approximately $253,000. 64.52% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/13/clsa-initiates-coverage-on-editas-medicine-edit.html.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

The Fly

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply